Kamada signs three-year USD 50 million plasma supply agreement with biopharmaceutical company
KMDA•Supply source and strategy
Plasma will be sourced from its Texas collection centers, supporting its vertical integration and plasma sales ramp-up strategy.
Three-year plasma supply deal
Kamada signed a three-year plasma supply agreement valued at about USD 50 million with a major plasma-derived therapies company.
Revenue is expected to be recorded starting in Q4 2026, with sales over the three-year term.
